Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYP3A4 Interaction Potential of GSK3772701 in Healthy Participants
NCT07670377Phase 1Completed
- Sponsor
- GSK
- Start
- Jun 2026
- Primary completion
- Aug 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MMV367 in Malaria, sponsored by GSK. Primary endpoints: Maximum observed concentration of MDZ at 24 hours, Area under the concentration-time curve from time 0 to the last measurable concentration of MDZ at 24 hours and 1 more. Started Jun 2026; status: completed.
02
Drugs
MMV367
03
Conditions
Malaria
Beyond the preview
Go deeper on NCT07670377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07670377.